Herb drug interaction: effect of Manix® on pharmacokinetic parameters of pefloxacin in rat model.

Sunday Odunke Nduka; Eleje Okonta; Chika Christiana Abba; Peter Chibueze Ihekwereme; Uchenna Ekwedigwe; Matthew Okonta

Return

Herb drug interaction: effect of Manix® on pharmacokinetic parameters of pefloxacin in rat model.

Author: Sunday Odunke NDUKA ¹ ; Eleje OKONTA ² ; Chika Christiana ABBA ³ ; Peter Chibueze IHEKWEREME ⁴ ; Uchenna EKWEDIGWE ² ; Matthew OKONTA ²
Author Information

1. Department of Clinical Pharmacy and Pharmacy Management, Nnamdi Azikiwe University, Awka, Anambra State, Nigeria.
2. Department of Clinical Pharmacy and Pharmacy Management, University of Nigeria, Nsukka, Enugu State, Nigeria.
3. Department of Pharmaceutical Chemistry, Nnamdi Azikiwe University, Awka, Anambra State, Nigeria.
4. Department of Pharmacology and Toxicology, Nnamdi Azikiwe University, Awka, Anambra State, Nigeria.
Publication Type:Journal Article
Keywords: Bioavailability; Escherichia coli; Manix®; Microbiological assay; Pefloxacin
From:Asian Pacific Journal of Tropical Biomedicine 2014;4(Suppl 1):S413-6
CountryChina
Language:English
Abstract:
OBJECTIVETo evaluate the effect of Manix®, the commonly used polyherbal formulation on pefloxacin pharmacokinetic parameters.
METHODSMicrobiological assay was employed using clinical isolate of Escherichia coli samples from hospitalized patients.
RESULTSManix® altered the bioavailability parameters of pefloxacin as thus, maximal concentration (Cmax) of pefloxacin (0.91±0.31) µg/mL occurred at time to reach maximal concentration (tmax) 4.0 h while in the group that received Manix® alongside pefloxacin Cmax was (0.22±0.08) µg/mL at tmax 1.0 h respectively. The area under curve of pefloxacin alone was (7.83±5.14) µg/h/mL while with Manix® was (2.60±0.08) µg/h/mL. There was a significant difference between Cmax, tmax and area under curve between pefloxacin alone and pefloxacin after Manix® pre-treatment (P<0.05).
CONCLUSIONSThe concurrent use of Manix® and pefloxacin has been found to compromise the therapeutic effectiveness of pefloxacin which could lead to poor clinical outcomes in patients.